progenity
presents
data
abstract
novel
ingestible
american
college
gastroenterology
acg
virtual
annual
meeting
san
diego
globe
newswire
progenity
nasdaq
prog
biotechnology
company
established
track
record
success
developing
commercializing
molecular
testing
products
innovation
field
gastrointestinal
precision
medicine
pleased
announce
oral
presentation
awarded
category
award
small
intestine
poster
related
progenity
ingestible
laboratory
diagnostics
pil
dx
capsule
sibo
presented
american
college
gastroenterology
acg
virtual
annual
meeting
taking
place
october
data
presentations
demonstrate
achievement
critical
steps
progenity
progress
toward
novel
approaches
assessment
diagnosis
future
treatment
gastrointestinal
diseases
ingestible
capsule
devices
small
intestinal
bacterial
growth
sibo
abnormal
overgrowth
bacteria
small
bowel
signs
symptoms
overlap
gastrointestinal
diseases
leading
million
patient
visits
us
annually
current
diagnostic
methods
invasive
inaccurate
often
leads
empiric
use
antibiotics
without
clear
diagnosis
pil
dx
ingestible
capsule
assay
fluorescent
spectrophotometer
designed
achieve
targeted
localization
collect
analyze
intestinal
fluid
samples
transmit
data
real
time
without
need
recover
capsule
pil
dx
represents
promising
alternative
diagnosing
sibo
eventually
gi
disorders
oral
presentation
renowned
gastroenterologist
satish
rao
md
phd
facg
highlights
results
study
subjects
benchtop
version
progenity
sibo
assay
showed
agreement
current
standard
endoscopic
aspiration
total
bacterial
count
pleased
results
collaborative
research
data
highlight
potential
innovative
technologies
developed
progenity
advance
field
provide
less
invasive
yet
accurate
tools
diagnose
sibo
said
rao
studies
showcased
acg
indicate
promising
progress
towards
ingestible
autonomous
assays
could
one
day
become
gold
standard
gi
diagnostics
today
none
poster
presentation
showcases
physician
research
expert
analysis
need
novel
sibo
diagnostic
clear
physician
preference
pil
dx
product
concept
existing
testing
options
enthusiastic
reception
data
gi
community
points
clear
unmet
need
new
tools
better
diagnose
differentiate
sibo
gastrointestinal
disorders
pil
dx
digital
laboratory
provide
simple
rapid
relatively
solution
accuracy
comparable
current
reference
standards
said
harry
stylli
phd
ceo
chairman
progenity
studies
represent
achievement
critical
milestone
continue
advance
pil
dx
platform
towards
preclinical
clinical
studies
ultimately
commercialization
goal
offer
true
precision
medicine
combining
novel
diagnostics
therapeutic
presentation
details
evaluation
smart
capsule
bacterial
detection
system
scbds
assay
duodenal
culture
subjects
suspected
sibo
undergoing
upper
endoscopy
interim
analysis
presenting
author
satish
rao
md
phd
professor
medicine
medical
college
georgia
augusta
university
abstract
id
sibo
diagnosis
clinical
survey
practice
patterns
unmet
needs
perception
novel
ingestible
diagnostic
capsule
presenting
author
baharak
moshiree
md
msc
professor
medicine
atrium
health
university
north
carolina
poster
number
abstracts
presentations
available
view
demand
acg
virtual
annual
meeting
website
well
progenity
website
following
meeting
progenity
progenity
biotechnology
company
established
track
record
success
developing
commercializing
molecular
testing
products
well
innovating
field
precision
medicine
progenity
provides
vitro
molecular
tests
designed
improve
lives
providing
actionable
information
helps
guide
patients
physicians
making
medical
decisions
key
life
stages
company
applies
approach
combining
genomics
epigenomics
proteomics
metabolomics
molecular
testing
products
development
suite
investigational
ingestible
devices
designed
provide
precise
diagnostic
sampling
drug
delivery
solutions
progenity
vision
transform
healthcare
become
precise
personal
improving
diagnoses
disease
improving
patient
outcomes
localized
treatment
targeted
therapies
information
progenity
helping
clinicians
patients
prepare
life
please
visit
forward
looking
statements
press
release
contains
statements
within
meaning
federal
securities
laws
statements
subject
substantial
risks
uncertainties
based
estimates
assumptions
statements
statements
historical
facts
included
press
release
including
statements
concerning
progress
timing
research
development
efforts
including
clinical
trials
timing
regulatory
approvals
statements
cases
identify
statements
terms
may
might
objective
intend
could
would
expect
believe
design
estimate
predict
potential
plan
negative
terms
similar
expressions
intended
identify
statements
statements
involve
known
unknown
risks
uncertainties
factors
could
cause
company
actual
results
differ
materially
statements
expressed
implied
press
release
including
described
risk
factors
management
discussion
analysis
financial
condition
results
operations
progenity
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
progenity
claims
protection
safe
harbor
contained
private
securities
litigation
reform
act
statements
progenity
expressly
disclaims
obligation
update
alter
statements
whether
result
new
information
future
events
otherwise
except
required
law
investor
contact
robert
uhl
managing
director
westwicke
icr
ir
